Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.12.004

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Demands for Access to New Therapies: Are There Alternatives to Accelerated Access?

British Medical Journal
Medicine
2017English

Pmh49 - Launching Long Acting Products to Treat Opioid Use Disorder: Are Payers Willing to Pay Premium Price?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Are Young Injection Drug Users Ready and Willing to Participate in Preventive HCV Vaccine Trials?

Vaccine
Molecular MedicinePublic HealthVeterinaryMicrobiology EnvironmentalImmunologyInfectious DiseasesOccupational Health
2010English

SP0071 Young Patients: Ready, Brilliant and Able to Work!

2017English

Are Global Health Systems Ready for Transformative Therapies?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Willing and Able: The Coordination Between Sexual Displays and Fertility

Neuron
Neuroscience
2016English

Equity of Access to Psychological Therapies

British Journal of Psychiatry
MedicinePsychiatryMental Health
2011English

Access to New Therapies in Romania Through the Scorecard HTA System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Are Australian Pharmacists Willing to Work in a Disaster?

Prehospital and Disaster Medicine
Emergency NursingEmergency Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy